Amrita Krishnan
City of Hope Medical Center · City of Hope National Medical Center, Duarte, CA
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Amrita Krishnan as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:16 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT04071457 · S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy DurationSWOG Cancer Research Network · active not recruiting · Multiple Myeloma · principal investigator
- Ph1NCT03591744 · Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell LeukemiaCity of Hope Medical Center · withdrawn · Plasma Cell Leukemia · principal investigator
- Ph1NCT03311828 · Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple MyelomaCity of Hope Medical Center · completed · Recurrent Plasma Cell Myeloma, Plasma Cell Myeloma, Secondary Amyloidosis · principal investigator
- Ph1NCT02337985 · Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin LymphomaCity of Hope Medical Center · active not recruiting · AIDS-Related Burkitt Lymphoma, AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Plasmablastic Lymphoma · principal investigator
- Ph1/Ph2NCT02119468 · Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple MyelomaCity of Hope Medical Center · completed · Refractory Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma · principal investigator
- Ph1NCT01961063 · Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin LymphomaCity of Hope Medical Center · active not recruiting · AIDS-related Non-Hodgkin Lymphoma, AIDS-related Plasmablastic Lymphoma, AIDS-related Primary Effusion Lymphoma · principal investigator
- Ph1NCT01074060 · Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple MyelomaCity of Hope Medical Center · completed · Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma · principal investigator
- Ph3NCT00491491 · Zevalin-beam for Aggressive LymphomaSheba Medical Center · completed · Non-Hodgkin's Lymphoma · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:16 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DAWN HERSHMAN, PRIMO N. LARA · fiscal years 2014 to 2026Named on NCT04071457
- Stem Cell Gene Therapy Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS PatientU01CA183012 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI John A Zaia · fiscal years 2014 to 2017Named on NCT02337985
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:16 UTC. The ranking covers the 200 most relevant of 115 PubMed records, and a shared surname and initials can bring in a namesake. All 115 on PubMed
- 1,198 citationsRCR 43.0
- Teclistamab in Relapsed or Refractory Multiple Myeloma.N Engl J Med · 20221,126 citationsRCR 79.2
- 715 citationsRCR 23.2
- Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.N Engl J Med · 2022670 citationsRCR 46.2
- Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.J Clin Oncol · 2006610 citationsRCR 12.2
- Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.Blood · 2017376 citationsRCR 12.5
- Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission.N Engl J Med · 2008345 citationsRCR 9.7
- RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma.Sci Transl Med · 2010310 citationsRCR 7.0
- 293 citationsRCR 14.8
- 272 citationsRCR 5.8